The drug rucaparib significantly delayed cancer progression for women with ovarian cancer and may be an effective option for maintenance therapy, according to findings from a recent clinical trial.
Biological sex has a small but ubiquitous influence on gene expression in almost every type of human tissue, according to a new study.
A new combination therapy targeting breast cancer tumors in the brain dramatically decreased tumor size and increased survival in mice, according to a new study.
A new patient-centered decision support tool aims to help pregnant women decide whether they prefer trial-of-labor or a repeat cesarean delivery after having a prior cesarean.
Machine-learning technology could help pathologists more accurately assess how a patient’s immune system is responding to breast cancer, according to a recent series of reports authored in part by Feinberg faculty.
In women with early-stage breast cancer, Northwestern Medicine investigators found chemoendocrine therapy was associated with greater cognitive impairment at three and six months compared to endocrine therapy alone.
A recent Northwestern Medicine study has identified that a transcription factor protein called AP-1 regulates gene enhancers that may be responsible for promoting the development of uterine fibroids.
Elagolix, a newly developed orally administered drug, was effective in reducing heavy menstrual bleeding in women with uterine fibroids, according to a recent Northwestern Medicine clinical trial.
A new review has found that a combination of endocrine inhibitors and hormone therapy is more effective in prolonging progression-free survival for advanced breast cancer patients, as compared to chemotherapy.